Concepedia

David De Witt

DD

Statistics

Publications

2

Citations

1.3K

H-Index

2

Active since

2012

Affiliations

AstraZeneca (United States)(Current)

David De Witt is an author at AstraZeneca (United States) specializing in nanocarriers for therapeutics, cancer nanotherapy, and cancer nanomedicine.

Publications per year

2012–2016

2

Publications

2

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali et al. · Science Translational Medicine · 2012 · 1.1K citations

, , +17

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Susan Ashton, Young Ho Song, Elaine Cadogan et al. · Science Translational Medicine · 2016 · 220 citations

, , +17

1–2 of 2